Common extrahepatic metastatic sites of hepatocellular carcinoma (HCC) include the lungs, peritoneum, adrenal glands and bone.\[[@ref1]\] Moreover, solitary pelvic extrahepatic metastasis is extremely rare with only two cases reported in the English literature.\[[@ref2]\] The majority of recurrences occur relatively early after initial diagnosis and treatment; the reported median duration between initial treatment for HCC to extrahepatic spread is 23.2 months.\[[@ref3]\] However, the present case is extremely rare as HCC recurred 28 years after the initial diagnosis and treatment. There has only been one previous report of extrahepatic recurrence occurring 10 years after initial treatment.\[[@ref4]\] The role of minimally invasive surgery for the treatment of extrahepatic metastasis is limited. Only one case report has demonstrated the successful laparoscopic extirpation of peritoneal dissemination of HCC.\[[@ref5]\] To the best of our knowledge, the current report is the first to describe a case of late solitary pelvic recurrence of hepatocellular carcinoma mimicking alpha-fetoprotein (AFP) producing gynaecologic tumour, which was successfully excised laparoscopically.

A 71-year-old woman with a history of HCC secondary to chronic infection with hepatitis B virus was admitted for the evaluation of a pelvic solid mass. She was initially diagnosed with HCC 28 years ago and underwent left lobectomy of the liver. Computed tomographic (CT) imaging of the abdomen indicated a 6.5 cm × 6 cm × 5 cm well-circumscribed, contrast-enhanced mass lesion in the right pelvis, which was suspected to be a subserosal uterine myoma \[[Figure 1a](#F1){ref-type="fig"}\]. Magnetic resonance imaging of the pelvis demonstrated a mass in the right pelvic cavity measuring 6.5 cm × 6 cm × 5 cm. This mass exhibited heterogeneous signal intensity on the T2-weighted image; therefore, it was suspected to be a degenerative uterine myoma or ovarian fibroma \[[Figure 1b](#F1){ref-type="fig"}\]. No space-occupying lesions in the liver or ascites were detected. CA-125 levels were within normal limits; however, the serum AFP level was 875.7 ng/mL.

![(a) Computed tomography demonstrates the contrast-enhanced mass in the right pelvic cavity (white arrowhead). (b) Magnetic resonance image indicates well-defined and heterogeneous mass in the right pelvic cavity in the T2-weighted image (white arrowhead)](JMAS-14-74-g001){#F1}

The patient underwent surgery following the tentative diagnosis of AFP-producing gynaecologic tumours. During surgery, a large vascular, friable and exophytic tumour was detected in the right pelvic cavity \[[Figure 2a](#F2){ref-type="fig"}\]. The tumour was adhesive to the surrounding tissue, particularly the bladder, and was quite friable, to the extent that it inadvertently ruptured despite careful dissection. During the excision of the tumour, bladder mucosa was exposed and primary repair was conducted with 2-0 Vicryl^®^ (Ethicon, Edinburgh, UK). Subsequently, the patient underwent laparoscopic pelvic mass excision, total hysterectomy and bilateral salpingo-oophorectomy \[[Figure 2b](#F2){ref-type="fig"}\]. The post-operative course was uneventful and the patient was discharged 3 days after the surgery. Histopathologic finding and immunochemical staining results indicated metastatic HCC. Following surgery, the patient\'s serum AFP level normalised. As there was no evidence of another systemic recurrence, no adjuvant chemotherapy was administered. The patient remained in good health 15 months after the surgery and her serum AFP remained normal. The latest CT scan was performed 1 year post-surgery and indicated no evidence of recurrence.

![(a) Intra-operative laparoscopic view. (b) Post-operative laparoscopic view](JMAS-14-74-g002){#F2}

The diagnosis of extrahepatic metastasis should always be suspected in cases with a solitary pelvic mass accompanied by a high serum AFP level and a history of HCC. Laparoscopic surgery may be successful in selected cases with extrahepatic metastasis of HCC.
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